Everett Harris & Co. CA Purchases 7,565 Shares of Henry Schein, Inc. $HSIC

Everett Harris & Co. CA boosted its position in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 4.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 168,218 shares of the company’s stock after acquiring an additional 7,565 shares during the period. Everett Harris & Co. CA’s holdings in Henry Schein were worth $12,714,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in HSIC. Ameriprise Financial Inc. raised its stake in Henry Schein by 3,275.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,266,858 shares of the company’s stock worth $165,594,000 after acquiring an additional 2,199,695 shares during the period. Norges Bank bought a new stake in Henry Schein during the 4th quarter worth approximately $88,116,000. Bank of America Corp DE raised its stake in Henry Schein by 204.2% during the 2nd quarter. Bank of America Corp DE now owns 995,375 shares of the company’s stock worth $72,712,000 after acquiring an additional 668,182 shares during the period. SG Americas Securities LLC raised its stake in Henry Schein by 171.9% during the 4th quarter. SG Americas Securities LLC now owns 820,698 shares of the company’s stock worth $62,028,000 after acquiring an additional 518,914 shares during the period. Finally, Artisan Partners Limited Partnership raised its stake in Henry Schein by 5.7% during the 3rd quarter. Artisan Partners Limited Partnership now owns 6,833,041 shares of the company’s stock worth $453,509,000 after acquiring an additional 370,837 shares during the period. Institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 0.8%

Shares of HSIC opened at $78.05 on Tuesday. The company’s fifty day moving average is $74.79 and its 200 day moving average is $76.01. Henry Schein, Inc. has a fifty-two week low of $61.94 and a fifty-two week high of $89.29. The stock has a market capitalization of $8.89 billion, a PE ratio of 23.58, a P/E/G ratio of 1.49 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.75 and a current ratio of 1.36.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $1.32 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.12. Henry Schein had a net margin of 2.95% and a return on equity of 15.44%. The company had revenue of $3.37 billion for the quarter, compared to analysts’ expectations of $3.34 billion. During the same quarter in the previous year, the business posted $1.15 earnings per share. Henry Schein’s quarterly revenue was up 6.3% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Sell-side analysts expect that Henry Schein, Inc. will post 5.32 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HSIC has been the topic of a number of recent analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Henry Schein in a research note on Monday, May 4th. Mizuho reduced their price objective on shares of Henry Schein from $88.00 to $82.00 and set a “neutral” rating on the stock in a research report on Wednesday, May 6th. BTIG Research began coverage on shares of Henry Schein in a research report on Thursday, April 16th. They set a “neutral” rating on the stock. Robert W. Baird set a $97.00 price objective on shares of Henry Schein in a research report on Wednesday, May 6th. Finally, Wells Fargo & Company lifted their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $86.83.

Insider Buying and Selling at Henry Schein

In related news, CEO Thomas C. Popeck sold 1,355 shares of the business’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the sale, the chief executive officer owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William K. Daniel purchased 10,000 shares of Henry Schein stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average price of $69.19 per share, for a total transaction of $691,900.00. Following the transaction, the director directly owned 20,000 shares of the company’s stock, valued at $1,383,800. The trade was a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.89% of the company’s stock.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.